Hims & Hers faces backlash over ‘misleading’ Super Bowl ad—but it didn’t stop stock from jumping over 11%

The telehealth company defended its ad with a defiant statement: ‘We’ve called out the system and now the system is asking that our ad get taken down.’

Telehealth company Hims & Hers Health is fighting back after the drug industry’s main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of marketing rules.